Patents by Inventor Agnieszka Dreas

Agnieszka Dreas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases
    Patent number: 10577365
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 3, 2020
    Assignees: Felicitex Therapeutics, Inc., Selvita S.A.
    Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
  • PYRIDONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
    Publication number: 20180305331
    Abstract: Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.
    Type: Application
    Filed: October 20, 2016
    Publication date: October 25, 2018
    Applicant: SELVITA S.A.
    Inventors: Tomasz RZYMSKI, Mariusz MILIK, Krzysztof BRZOZKA, Charles-Henry FABRITIUS, Katarzyna KUCWAJ-BRYSZ, Urszula KULESZA, Ewelina WINCZA, Agnieszka DREAS, Michal GALEZOWSKI
  • DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES
    Publication number: 20180179199
    Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 20, 2017
    Publication date: June 28, 2018
    Applicants: Felicitex Therapeutics, Inc., Selvita S.A.
    Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
  • Substituted tricyclic benzimidazoles as kinase inhibitors
    Patent number: 9745299
    Abstract: Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: August 29, 2017
    Assignee: SELVITA SA
    Inventors: Tomasz Rzymski, Adrian Zarebski, Agnieszka Dreas, Karolina Osowska, Katarzyna Kucwaj, Joanna Fogt, Marek Cholody, Michal Galezowski, Wojciech Czardybon, Raymond Horvath, Katarzyna Wiklik, Mariusz Milik, Krzysztof Brzózka
  • SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS
    Publication number: 20150274726
    Abstract: Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 1, 2015
    Inventors: Tomasz Rzymski, Adrian Zarebski, Agnieszka Dreas, Karolina Osowska, Katarzyna Kucwaj, Joanna Fogt, Marek Cholody, Michal Galezowski, Wojciech Czardybon, Raymond Horvath, Katarzyna Wiklik, Mariusz Milik, Krzysztof Brzózka